Department of Internal Diseases, Riga Stradins University, LV-1079 Riga, Latvia.
Clinic of Nephrology and Renal Replacement Therapy, Riga East University Hospital, LV-1079 Riga, Latvia.
Medicina (Kaunas). 2021 Jul 6;57(7):689. doi: 10.3390/medicina57070689.
At present, there is insufficient evidence to support the use of continuous veno-venous haemofiltration (CVVH) in the early treatment of septic shock. This study focuses on the association between survival and different parameters of oxidative stress (RedOx). Thereby, we evaluated whether RedOx markers are associated with the outcome of septic shock in patients under early-initiated CVVH treatment. We conducted a prospective observational study of 65 patients with septic shock who started CVVH within 12 h after hospital admission. Blood samples were taken from each patient prior to the start of CVVH. The following RedOx markers were measured: glutathione peroxidase, glutathione reductase (GR), total antioxidant capacity, superoxide dismutase, nitric oxide, malondialdehyde and 4-hydroxynonenal. The odds ratio (OR) was calculated using binary logistic regression and stepwise multivariable regression. The 65 patients had a median age of 66 years and 39 were male. Based on the outcome, the patients were divided into two groups-non-survivors ( = 29) and survivors ( = 36)-and the levels of RedOx markers were compared between them. Of all the markers, only higher GR activity was found to be significantly associated with the fatal outcome; 100.3 U/L versus 60.5 U/L, OR = 1.027 (95% CI, 1.010-1.044). Following adjustment for the sequential organ failure assessment score and other parameters, GR activity still presented a significant association with the fatal outcome, OR = 1.020 (95% CI, 1.002-1.038). GR activity is associated with in-hospital fatal outcomes among septic shock patients under early-initiated CVVH treatment. Septic shock patients who have a lower GR activity at hospital admission may have a favourable outcome of the early initiation of CVVH.
目前,尚无足够证据支持连续性静脉-静脉血液滤过(CVVH)在脓毒性休克的早期治疗中的应用。本研究重点关注氧化应激(RedOx)的不同参数与生存之间的关系。因此,我们评估了 RedOx 标志物是否与早期开始 CVVH 治疗的脓毒性休克患者的结局相关。
我们对 65 例在入院后 12 小时内开始 CVVH 的脓毒性休克患者进行了前瞻性观察性研究。在开始 CVVH 之前,从每位患者采集血液样本。测量了以下 RedOx 标志物:谷胱甘肽过氧化物酶、谷胱甘肽还原酶(GR)、总抗氧化能力、超氧化物歧化酶、一氧化氮、丙二醛和 4-羟基壬烯醛。使用二项逻辑回归和逐步多变量回归计算比值比(OR)。
65 例患者的中位年龄为 66 岁,39 例为男性。根据结局,将患者分为两组-非幸存者(n=29)和幸存者(n=36)-并比较两组之间的 RedOx 标志物水平。在所有标志物中,只有更高的 GR 活性与致命结局显著相关;100.3 U/L 与 60.5 U/L,OR=1.027(95%CI,1.010-1.044)。在调整序贯器官衰竭评估评分和其他参数后,GR 活性仍与致命结局显著相关,OR=1.020(95%CI,1.002-1.038)。
GR 活性与早期开始 CVVH 治疗的脓毒性休克患者的院内病死率相关。入院时 GR 活性较低的脓毒性休克患者,早期开始 CVVH 可能有较好的结局。